MedTrace Logo

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

NCT05156827 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-01-12

No results posted yet for this study

Summary

This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

TB006

TB006 diluted in normal saline, administered through IV infusion over an hour

DRUG

Placebo

Normal saline administered through IV infusion over an hour

Sponsors & Collaborators

  • TrueBinding, Inc.

    lead INDUSTRY

Principal Investigators

  • TrueBinding, Inc. · TrueBinding, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2023-12-18
Completion
2023-12-18
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05156827 on ClinicalTrials.gov